| 王 彧,高腾君,苗有泉,许志华,阿尖措.分析塞来昔布与不同剂量艾瑞昔布治疗axSpA的效果及对骨代谢的影响[J].,2020,(3):553-557 |
| 分析塞来昔布与不同剂量艾瑞昔布治疗axSpA的效果及对骨代谢的影响 |
| Effects of Celecoxib and Different Doses of Imrecoxib in the Treatment of axSpA and Their Influence on Bone Metabolism |
| 投稿时间：2019-04-26 修订日期：2019-05-23 |
| DOI：10.13241/j.cnki.pmb.2020.03.033 |
| 中文关键词: 中轴脊柱关节炎 艾瑞昔布 塞来昔布 骨代谢 |
| 英文关键词: Axial spondyloarthritis Imrecoxib Celecoxib Bone metabolism |
| 基金项目:青海省科技厅科学研究项目（2019-wjzdx-77 ） |
|
| 摘要点击次数: 909 |
| 全文下载次数: 632 |
| 中文摘要: |
| 摘要 目的：探究塞来昔布和2种剂量艾瑞昔布治疗中轴脊柱关节炎(axSpA)的效果及对患者骨代谢的影响。方法：选取我院96例axSpA患者为研究对象，采用随机数字表法分为A组、B组、C组各32例。A组给予0.2 g/d艾瑞昔布治疗，B组给予0.4 g/d艾瑞昔布治疗C组给予0.4 g/d塞来昔布治疗。比较3组治疗前及治疗12周后疾病活动性[C反应蛋白(CRP)、红细胞沉降率(ESR)、Bath强直性脊柱炎疾病活动指数(BASDAI)]、躯体活动度（踝间距、腰椎侧弯度）、功能状态[Bath强直性脊柱炎功能指数(BASFI)、加拿大脊柱骨关节研究协会评分系统(SPARCC)]、骨代谢[血清骨形成发生蛋白-2(BMP-2)、血管内皮生长因子(VEGF)、Dickkopf相关蛋白1(DKK-1)]差异，并记录3组治疗期间不良反应发生情况。结果：治疗12周后，3组疾病活动性（CRP、ESR、BASDAI）、功能状态（BASFI、SPARCC）、骨代谢（BMP-2、VEGF、DKK-1）均较治疗前降低（P＜0.05），躯体活动度（踝间距及左右侧腰椎侧弯度）则较治疗前升高（P＜0.05）；但B组及C组组间比较，差异无统计学意义（P＞0.05），而A组上述指标变化幅度低于B组及C组（P＜0.05）。3组治疗期间不良反应发生情况比较，差异均无统计学意义（P＞0.05）。结论：较高剂量（0.4 g/d）艾瑞昔布疗效明显优于较低剂量（0.2 g/d），不良反应也未增加，且0.4 g/d艾瑞昔布及同剂量塞来昔布治疗axSpA具有相似的疗效及安全性，适用于临床治疗。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effects of celecoxib and two doses of imrecoxib in the treatment of axial spondyloarthritis (axSpA) and their influence on bone metabolism. Methods: 96 patients with axSpA in our hospital were selected as the study subjects and were divided into group A, group B and group C according to the random number table method, with 32 cases in each group. Group A was treated with 0.2 g/d imrecoxib, and group B was given 0.4 g/d imrecoxib, and group C was given 0.4 g/d celecoxib. The disease activity[C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)], body activity (ankle spacing, lumbar vertebrae lateral curvature), functional status[Bath Ankylosing Spondylitis Functional Index (BASFI), Canadian Spinal and Bone Joint Research Association Scoring System (SPARCC)] and bone metabolism [bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor (VEGF) and Dickkopf-related protein 1(DKK-1)] were compared among the three groups before treatment and after 12 w of treatment, and the occurrence of adverse reactions during treatment was recorded in the three groups. Results: After 12 w of treatment, the disease activity (CRP, ESR, BASDAI), functional status (BASFI, SPARCC) and bone metabolism (BMP-2, VEGF, DKK-1) in the three groups were lower than those before treatment(P<0.05), and the body activity (ankle spacing, left and right lateral curvature of lumbar vertebrae) was higher than that before treatment(P<0.05), However, there were no significant differences between group B and group C(P>0.05), and the changes of above indicators in group A were lower than those in group B and group C(P<0.05). There were no significant differences in adverse reactions among the three groups during treatment (P>0.05). Conclusion: The higher dose(0.4 g/d) imrecoxib has better efficacy than the lower dose(0.2 g/d), and it does not increase adverse reactions, and 0.4 g/d imrecoxib and the same dose of celecoxib have similar efficacy and safety in the treatment of axSpA, and it is suitable for clinical treatment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
